FAQ on Scinai Immunotherapeutics' $2M Investment Commitment Agreement

What is the main topic of the press release?

The press release announces that Scinai Immunotherapeutics has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of its largest shareholder, Mr. Daniel Stone.

Why is this agreement significant for Scinai Immunotherapeutics?

This agreement provides Scinai with the flexibility to issue and sell ASDs for up to $2 million by December 31, 2024, offering a financial boost without the requirement to register these securities for resale.

How does the Investment Commitment Agreement work?

Under the agreement, Scinai may issue and sell ASDs to RK Stone Miami LLC from time to time through December 31, 2024, for an aggregate purchase price of up to $2 million.

Who is involved in this agreement?

The agreement is between Scinai Immunotherapeutics and RK Stone Miami LLC, an affiliate of Mr. Daniel Stone, the largest shareholder of Scinai.

When does this agreement take effect and until when?

The agreement allows Scinai to issue and sell ASDs from the time of the agreement until December 31, 2024.

What are the implications of this agreement for Scinai?

This agreement enables Scinai to secure up to $2 million in funding by selling ASDs, providing financial support for its operations and development projects without the need to register these securities for resale.

Where can I find more information about Scinai Immunotherapeutics?

For more information, visit the company’s website at www.Scinai.com or the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.

What should investors know about this agreement?

Investors should note that this agreement provides Scinai with a flexible funding option without the immediate need to register the ASDs for resale, potentially supporting the company’s growth and development efforts.